OR WAIT null SECS
September 17, 2025
Video
Saggese explains the importance of effective communication in MASH management and emphasizes the need for more therapies to offer patients.
September 15, 2025
Article
An audio recap of the top 5 stories in healthcare news from the week of 9/5-9/13.
Moore discusses the importance of individualizing PBC treatment now that multiple second-line therapies are available.
September 13, 2025
Stay updated with the latest healthcare breakthroughs, including FDA news and the voluntary withdrawal of obeticholic acid, in this week's essential news roundup.
September 11, 2025
Intercept Pharmaceuticals has voluntarily withdrawn obeticholic acid from the US market following a request from the FDA.
September 10, 2025
Saggese describes recent evolutions in MASH care with the FDA approval of semaglutide and the continued importance of diet, physical activity, and weight management.
September 09, 2025
For the first time, the FDA has accepted the initiation of the qualification of an NIT as a noninvasive surrogate endpoint in drug development for MASH.
September 08, 2025
Moore describes recent progress in PBC and PSC and how this defined the field of hepatology in 2024, with lasting effects into 2025.
September 06, 2025
Stay updated with the latest healthcare breakthroughs, including FDA news and phase 3 clinical trial data, in this week's essential news roundup.
September 04, 2025
Findings highlight a 33% increase in 1-year and nearly 50% increase in 5-year post-transplant survival with a living versus deceased donor transplant.
